You are viewing a free preview of this lesson.
Subscribe to unlock all 11 lessons in this course and every other course on LearningBro.
The Edexcel specification pairs its classic study with a contemporary study, so that you can compare how the field's methods and conclusions have moved on. Rosenhan (1973) is a behaviourally focused, critical field study that questioned whether diagnosis corresponds to anything real; the contemporary study examined here — Carlsson, Waters, Waters and Carlsson (2000), "Network interactions in schizophrenia — therapeutic implications" — sits at the opposite methodological pole. It is a biological review that takes schizophrenia seriously as a brain-based disorder and uses modern neuroimaging and pharmacology to build a multi-neurotransmitter, "network" model of its causes and treatment. Setting the two side by side captures the arc of clinical psychology over three decades: from doubting the validity of the label to mapping the neurochemistry beneath it. This lesson covers Carlsson et al.'s aim, methods, findings, conclusions and evaluation, and then draws the explicit classic-versus-contemporary comparison the specification expects. As throughout the topic, schizophrenia is discussed as a serious condition to be explained and treated, in a measured clinical register.
Key Definition: A contemporary study in the Edexcel scheme is a modern piece of research paired with the classic study so that students can compare methods, findings and conclusions across time. Network stabilisation is Carlsson et al.'s proposal that, because several interacting neurotransmitters are involved in schizophrenia, the therapeutic goal should be to restore balance across the network rather than to block a single transmitter.
This lesson addresses the Edexcel 9PS0 — Paper 2, Topic 5: Clinical Psychology requirement to study a contemporary study paired with the classic study, covered here through Carlsson et al. (2000): its aim, method (a theoretical review synthesising neuroimaging and pharmacological evidence), findings (the revised dopamine hypothesis; the glutamate/NMDA hypothesis; the interaction of dopamine, glutamate and GABA across brain pathways), conclusions (a multi-transmitter "network" model and network stabilisation as a treatment strategy), and its evaluation and comparison with the classic study. It draws directly on the biological-explanations and drug-treatment lessons for schizophrenia (the dopamine hypothesis and antipsychotic action) and completes the classic/contemporary pairing begun in the Rosenhan lesson. In assessment-objective terms, you should be able to describe the study accurately (AO1), apply its model to the explanation and treatment of schizophrenia (AO2), and evaluate it and compare it methodologically with the classic study (AO3).
Connects to…
By 2000, the classic dopamine hypothesis — that schizophrenia results from overactivity of dopamine, supported by the fact that antipsychotics block dopamine (D2) receptors and that dopamine-releasing drugs such as amphetamine can induce psychotic symptoms — was known to be incomplete. It struggled to explain the negative symptoms (flattened affect, avolition), the time lag before antipsychotics take effect, and the substantial minority of patients who did not respond to dopamine-blocking drugs at all (so-called treatment-resistant schizophrenia). At the same time, sophisticated neuroimaging was providing more direct evidence about dopamine function, and interest was growing in glutamate, prompted by the observation that drugs blocking the NMDA glutamate receptor produced schizophrenia-like states.
Against this background, Carlsson et al. (2000) aimed to review and integrate the evidence on the neurotransmitters and neural networks involved in schizophrenia, moving beyond a single-transmitter dopamine account towards a model in which several interacting neurotransmitters — dopamine, glutamate, serotonin and GABA — jointly regulate the relevant brain circuits. A closely linked aim was therapeutic: to identify why current treatments fail some patients and to propose new pharmacological strategies (targeting glutamate and serotonin as well as dopamine) that might help, especially treatment-resistant cases. Arvid Carlsson's own Nobel-recognised work on dopamine gave the review particular authority. The study is therefore a piece of theory-building grounded in accumulated empirical evidence, with an explicit eye to treatment.
Carlsson et al. (2000) is a theoretical review (a review/synthesis paper), not an experiment or a single empirical data-collection. Its "method" is the systematic marshalling and interpretation of evidence from several sources:
| Evidence source | What it contributed |
|---|---|
| Human neuroimaging (e.g. PET/SPECT studies of dopamine) | More direct, in-vivo evidence of dopamine dysfunction and its regional pattern in patients |
| Pharmacological evidence in humans | The effects of antipsychotics (dopamine blockers) and of psychotomimetic drugs (amphetamine; PCP and ketamine as NMDA antagonists) on symptoms |
| Animal models | Experimental manipulation of neurotransmitter systems to trace how dopamine, glutamate and GABA interact in defined pathways |
| Prior biochemical and post-mortem findings | Background on transmitter levels and receptor function in schizophrenia |
Because it is a review, the paper's strength lies in integration — combining strands that individually gave a partial picture into a single circuit-level model — rather than in a new controlled dataset. This methodological character is central to its evaluation and to the comparison with Rosenhan's field study.
It is worth being clear about what kind of claim a review of this sort can and cannot support. A review does not, by itself, establish new causal facts; its contribution is interpretive and integrative — it argues that a body of existing findings is best explained by a particular model. This gives it two properties that recur in the evaluation. First, its persuasiveness depends on the quality and independence of the studies it draws together: where several different methods (imaging in humans, drug effects in humans, circuit manipulations in animals) converge on the same conclusion, the model is well grounded; where the model leans on one method (notably animal work) the corresponding claims are weaker. Second, a review is a snapshot of the evidence at the time of writing, so a strong review can later be partly overtaken as new data arrive — which is exactly what has happened to some of the specific glutamate claims discussed below. Recognising the study as a piece of high-quality theory-building on existing evidence, rather than as a single decisive experiment, is the key to using it accurately.
To appreciate what Carlsson et al. contributed, it helps to restate the original dopamine hypothesis and its difficulties, since the review is essentially a response to them.
The original hypothesis held that the positive symptoms of schizophrenia result from overactivity of dopamine transmission, particularly an excess of dopamine or of dopamine (D2) receptor activity. Its support was substantial and is worth knowing:
| Line of evidence | What it showed |
|---|---|
| Antipsychotic (neuroleptic) action | Drugs that reduce psychotic symptoms are dopamine (D2) antagonists, and their clinical potency broadly tracks their D2-blocking strength |
| Amphetamine psychosis | Amphetamine, which increases dopamine release, can induce a state resembling paranoid schizophrenia in healthy people and worsen symptoms in patients |
| L-DOPA effects | L-DOPA, used to raise dopamine in Parkinson's disease, can produce psychotic side effects |
Despite this, the hypothesis faced well-known problems that a strong answer should be able to list, because they are precisely what the network model set out to solve:
These four problems are the backdrop to Carlsson et al.'s revision: a satisfactory model had to explain negative as well as positive symptoms, accommodate treatment resistance, and fit a regionally uneven, multi-transmitter reality rather than a single global excess.
The review's substantive content can be organised around three claims.
Carlsson et al. accepted that dopamine dysfunction is genuinely involved — now with direct imaging support — but argued it is not uniform across the brain. Rather than simple global overactivity, the disorder appears to involve too much dopamine activity in some pathways and too little in others:
| Pathway | Proposed dopamine state | Associated symptoms |
|---|---|---|
| Mesolimbic (limbic system) | Hyperdopaminergia — excess activity | Positive symptoms (hallucinations, delusions) |
| Mesocortical (prefrontal cortex) | Hypodopaminergia — reduced activity | Negative and cognitive symptoms (flat affect, avolition, poor cognition) |
This region-specific picture immediately explains something the original hypothesis could not: why simply blocking dopamine everywhere (as typical antipsychotics do) can relieve positive symptoms while leaving negative symptoms untouched, or even worsening them.
The review gave glutamate a leading role, drawing on the key observation that NMDA-receptor antagonists — PCP ("angel dust") and ketamine — induce a state closely resembling schizophrenia, including negative and cognitive symptoms, in healthy people. This piece of evidence is pivotal, so it is worth spelling out why it points to glutamate specifically. Glutamate is the brain's main excitatory transmitter, and the NMDA receptor is one of its principal receptor types; PCP and ketamine work by blocking NMDA receptors, thereby reducing glutamate signalling. If reducing NMDA/glutamate function reproduces the disorder — and, importantly, reproduces the negative and cognitive symptoms that the dopamine hypothesis struggled with, not just the positive ones — then reduced glutamate function (hypoglutamatergia) is a strong candidate cause of schizophrenia rather than a mere correlate. Crucially, Carlsson et al. proposed that glutamate does not act in isolation but regulates dopamine, functioning, in their memorable framing, as both an "accelerator" and a "brake" on dopamine firing depending on the pathway and on whether it acts directly or via inhibitory GABA interneurons. This regulatory relationship is what allows a single disturbance — reduced glutamate — to produce the opposite dopamine states (excess in one pathway, deficit in another) that the region-specific findings required.
The core theoretical move is that these transmitters form a regulatory network. In simplified terms:
graph TD
GLU["Cortical glutamate<br/>(NMDA receptors)"] -->|accelerator: direct excitation| DA["Dopamine neuron firing"]
GLU -->|drives| GABA["GABA interneuron"]
GABA -->|brake: inhibition| DA
LOWGLU["Hypoglutamatergia<br/>(reduced NMDA function)"] -.->|weakens brake in mesolimbic path| HYPER["Mesolimbic hyperdopaminergia<br/>→ positive symptoms"]
LOWGLU -.->|leaves cortex underactive| HYPO["Mesocortical hypodopaminergia<br/>→ negative/cognitive symptoms"]
style GLU fill:#2563eb,color:#fff
style HYPER fill:#e74c3c,color:#fff
style HYPO fill:#7c3aed,color:#fff
The upshot is a multi-transmitter, circuit-level model in which schizophrenia arises from dysregulation of an interacting dopamine–glutamate–GABA network, with serotonin also modulating the system — a substantial advance on "too much dopamine".
Carlsson et al. (2000) reached conclusions that were both explanatory and therapeutic.
In short, the study reframed schizophrenia's biology from a single-transmitter hypothesis to an integrated network model, and reframed its treatment from receptor-blockade to network stabilisation.
A major strength is that the network model has strong explanatory power, accounting for evidence the simple dopamine hypothesis could not. By making dopamine dysfunction region-specific and embedding it in a glutamate–GABA network, the model explains why antipsychotics relieve positive but not negative symptoms, why some patients are treatment-resistant, and why NMDA antagonists such as ketamine mimic the full range of symptoms. This matters because explanatory breadth is a key virtue of a scientific model. The implication is that Carlsson et al. offer a more complete and clinically useful account of schizophrenia's neurochemistry than the original hypothesis, which is why the multi-transmitter view has become mainstream.
The model is well supported by converging biological evidence, including modern neuroimaging and consistent drug effects. It draws on in-vivo imaging of dopamine function, the reliable psychotomimetic effects of PCP and ketamine, and the pharmacology of antipsychotics — several independent lines pointing the same way. This matters because convergence from different methods is far more persuasive than any single finding. The implication is that the network model rests on a robust evidential base, and its treatment predictions (that glutamatergic and serotonergic drugs should help) are directly testable, giving the theory scientific traction that a purely descriptive account would lack.
Subscribe to continue reading
Get full access to this lesson and all 11 lessons in this course.